Novavax (Germany) Top Insiders

NVV1 Stock  EUR 8.38  0.53  5.95%   
Novavax employs about 1.5 K people. The company is managed by 33 executives with a total tenure of roughly 171 years, averaging almost 5.0 years of service per executive, having 46.7 employees per reported executive. Examination of Novavax's management performance can provide insight into the company performance.
Stanley Erck  CEO
President, Chief Executive Officer, Director
Rick Crowley  President
Chief Operating Officer, Executive Vice President
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.

Novavax Management Team Effectiveness

The company has return on total asset (ROA) of (0.317) % which means that it has lost $0.317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.982) %, meaning that it generated substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities.

Novavax Workforce Comparison

Novavax is regarded third in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 10,967. Novavax retains roughly 1,541 in number of employees claiming about 14% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.72) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.66) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.66.

Novavax Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Novavax Price Series Summation is a cross summation of Novavax price series and its benchmark/peer.

Novavax Notable Stakeholders

A Novavax stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novavax often face trade-offs trying to please all of them. Novavax's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novavax's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stanley ErckPresident, Chief Executive Officer, DirectorProfile
Rick CrowleyChief Operating Officer, Executive Vice PresidentProfile
John TrizzinoExecutive Vice President, Chief Business Officer, Chief Financial Officer and TreasurerProfile
Gregory CovinoChief Financial Officer, Executive Vice PresidentProfile
MBA BSExec OfficerProfile
Jody LichaaSenior Vice President - Quality AssuranceProfile
Ben MachielseExecutive Vice President - CMCProfile
Michael McManusIndependent DirectorProfile
Brian WebbSenior Vice President - ManufacturingProfile
John HerrmannExecutive Vice President Chief Legal OfficerProfile
Filip DubovskySenior Vice President Chief Medical OfficerProfile
Rachel KingIndependent DirectorProfile
Gary EvansIndependent DirectorProfile
Margaret McGlynnIndependent DirectorProfile
Jill HoytChief Human Resource Officer, Executive Vice PresidentProfile
Erika TrahanAssociate PRProfile
Henrietta UkwuSenior Vice President Chief Regulatory and Quality OfficerProfile
Frank CzworkaSenior Vice President - Global SalesProfile
Gregg AltonDirectorProfile
James CFACFO VPProfile
Rajiv ModiDirectorProfile
JD EsqVP OfficerProfile
Brian RosenSenior Vice President - Commercial StrategyProfile
Richard CrowleyEx COOProfile
Silvia TaylorSenior Vice President of Investor Relations and Corporate AffairsProfile
John IIIChief VPProfile
Biegie LeeVP OfficerProfile
Gale SmithVP ScientistProfile
James YoungIndependent Chairman of the BoardProfile
Gregory GlennPresident Research and DevelopmentProfile
David MottIndependent DirectorProfile
Madelyn CaltabianoSenior Vice President - Global Program ManagementProfile
Richard DouglasIndependent DirectorProfile

About Novavax Management Performance

The success or failure of an entity such as Novavax often depends on how effective the management is. Novavax management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novavax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novavax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people.

Novavax Workforce Analysis

Traditionally, organizations such as Novavax use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novavax within its industry.

Novavax Manpower Efficiency

Return on Novavax Manpower

Revenue Per Employee743.9K
Revenue Per Executive34.7M
Net Loss Per Employee1.1M
Net Loss Per Executive52.8M

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Fundamental Analysis
View fundamental data based on most recent published financial statements